Psychiatry
Loading Add to Favorites
Share
Tweet
Cite
Metabolic monitoring for atypical antipsychotics
Note: more comprehensive or frequent monitoring may be needed if chronic medical conditions exist
[select name="Q1" value="Baseline|6 weeks after starting drug treatment|12 weeks after starting drug treatment|Annual"] <-- Interval
[conditional field="Q1" condition="(Q1).is('Baseline')||(Q1).is('Annual')"]Medical history
Blood pressure
Body mass index
Waist circumference
Fasting glucose level
Fasting lipid levels
Lifestyle counseling[/conditional][conditional field="Q1" condition="(Q1).is('6 weeks after starting drug treatment')||(Q1).is('12 weeks after starting drug treatment')"]Blood pressure
Body mass index
Fasting glucose level
Fasting lipid levels
Lifestyle counseling[/conditional]
[checkbox memo="display/hide references" name="footnotes" value=""][conditional field="footnotes" condition="(footnotes).is('')"]
reference:
[link url="//www.ncbi.nlm.nih.gov/pubmed/21804146" memo="#1"] De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, van Winkel R, Mitchell AJ. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011 Aug;199(2):99-105.
[link url="http://www.nimh.nih.gov/health/publications/mental-health-medications/index.shtml#pub4" memo="#2"] NIMH - Antipsychotic medications
[/conditional]
Metabolic monitoring for atypical antipsychotics
Note: more comprehensive or frequent monitoring may be needed if chronic medical conditions exist
<-- Interval

display/hide references
Result - Copy and paste this output: